A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI-386 Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects With Open-Label Follow-Up
Latest Information Update: 09 May 2023
At a glance
- Drugs Scopolamine (Primary)
- Indications Motion sickness; Nausea
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Repurposed Therapeutics
Most Recent Events
- 03 May 2023 Status changed from recruiting to completed.
- 02 Dec 2019 Planned End Date changed from 31 Dec 2019 to 1 Feb 2020.
- 02 Dec 2019 Planned primary completion date changed from 31 Aug 2019 to 1 Feb 2020.